-
GLOBAL REGULATORY ASYMMETRIES AND THE STRUCTURAL DRUG LAG: TIME TO MARKET AUTHORIZATION IN CÔTE D’IVOIRE
Mar 18, 2026, 21:38 PM -
GLOBAL BURDEN OF MULTIPLE SCLEROSIS AND FUTURE PROJECTIONS: EVIDENCE FROM GBD 2023
Mar 18, 2026, 21:38 PM -
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF INDIVIDUALS INITIATING GLP-1 AGONISTS FOR OBESITY: A CLAIMS DATABASE ANALYSIS IN THE US
Mar 18, 2026, 21:38 PM -
IMPACT OF ETEPLIRSEN TREATMENT INITIATION DELAYS ON LOSS OF AMBULATION INCIDENCE AMONG AMBULATORY PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY
Mar 18, 2026, 21:38 PM -
ECONOMIC IMPACT OF AN AI-ENABLED DIGITAL TWIN INTERVENTION IN TYPE 2 DIABETES
Mar 18, 2026, 21:38 PM -
EARLY EXPERIENCE WITH THE EUROPEAN UNION JOINT CLINICAL ASSESSMENT (EUJCA): IMPLICATIONS FOR ONCOLOGY PRODUCTS
Mar 18, 2026, 21:38 PM -
LEVERAGING HEALTH INSURANCE DATA FOR ACCELERATED AND TARGETED RECRUITMENT IN CLINICAL TRIALS IN GERMANY
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS AMONG PEOPLE WITH MODERATE-TO-SEVERE HEMOPHILIA A AND B IN CHINA: A RETROSPECTIVE DATABASE STUDY
Mar 18, 2026, 21:38 PM -
FROM EVIDENCE TO PRICE: EMBEDDING PRICING STRATEGY IN EARLY MARKET ACCESS PLANNING
Mar 18, 2026, 21:38 PM -
PREFERENCES AND TRADE-OFFS FOR MASLD/MASH TESTING AMONG PATIENTS WITH TYPE 2 DIABETES: A DISCRETE CHOICE EXPERIMENT
Mar 18, 2026, 21:38 PM -
THE EXTENT OF TREATMENT RESPONSE AND PREFERENCE HETEROGENEITY IN MAJOR DEPRESSIVE DISORDER: IMPLICATIONS FOR POPULATION-LEVEL RESOURCE ALLOCATION
Mar 18, 2026, 21:38 PM -
AN AUTOMATED FEASIBILITY ASSESSMENT TOOL FOR INDIRECT TREATMENT COMPARISONS ACROSS MULTIPLE ANALYTICAL METHODS
Mar 18, 2026, 21:38 PM -
COST OF ILLNESS AMONG ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (ADRD) MEDICARE PATIENTS IN THE UNITED STATES BETWEEN 2011-2021
Mar 18, 2026, 21:38 PM -
OBSERVED CARDIOVASCULAR DISEASE PREVALENCE AMONG OBESE AND TYPE 2 DIABETES PATIENTS WITH AND WITHOUT GLP-1 TREATMENT
Mar 18, 2026, 21:38 PM -
POWER, POLITICS, AND PRICE: GOVERNANCE FAILURES IN NEPAL’S PHARMACEUTICAL SYSTEM AND THE UHC CHALLENGE
Mar 18, 2026, 21:38 PM -
AN INDIRECT TREATMENT COMPARISON (ITC) OF IFINATAMAB DERUXTECAN (I-DXD) VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY (RWPCT) IN PATIENTS PREVIOUSLY TREATED WITH AT LEAST 2 LINES OF THERAPY (LOTS) FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER...
Mar 18, 2026, 21:38 PM -
REAL-WORLD OUTCOMES OF SECOND-LINE THERAPIES IN RELAPSED/REFRACTORY DLBCL PATIENTS IN GERMANY: IMPACT OF FRONT-LINE TREATMENT-FREE PERIOD (2020-2022)
Mar 18, 2026, 21:38 PM -
ASSESSING THE VALUE OF LOST SCHOOLING DUE TO ILLNESS AMONG CHILDREN IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION (HRU) AND COST BURDEN IN NON-METASTATIC MELANOMA IN THE MODERN TREATMENT ERA: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)-MEDICARE ANALYSIS
Mar 18, 2026, 21:38 PM -
HUMANISTIC BURDEN IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD) USING PATIENT-REPORTED OUTCOME MEASURES (PROMS)
Mar 18, 2026, 21:38 PM
